Immunosuppressive effect of budesonide on human lamina propria lymphocytes
| Autor: | Julie Dosescu, Steven N. Lichtman, Jeffrey A. Moshier, Cheryl Neace, Yoram Elitsur |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Interleukin 2
Budesonide Side effect Colon T-Lymphocytes Lymphocyte medicine.medical_treatment Anti-Inflammatory Agents In Vitro Techniques Biology Ornithine Decarboxylase Methylprednisolone Inflammatory bowel disease Immune system medicine Humans Intestinal Mucosa Cells Cultured Pharmacology Tumor Necrosis Factor-alpha DNA Adrenergic beta-Agonists medicine.disease medicine.anatomical_structure Cytokine Immunology Interleukin-2 Tumor necrosis factor alpha Cell Division Immunosuppressive Agents medicine.drug |
| Zdroj: | Immunopharmacology. 38:279-285 |
| ISSN: | 0162-3109 |
| DOI: | 10.1016/s0162-3109(97)00090-8 |
| Popis: | Budesonide, a beta-adreno-receptor agonist, is comparable to corticosteroid in the treatment of patients with inflammatory bowel disease with the advantage of minimal side effect. Although the immunomodulatory effects of budesonide on the circulatory and respiratory mucosal immune system have been reported, its effect on the human gut immune system has not been published. In this study, the effect of budesonide on the human gut immune system was compared to methyl-prednisolone. The cellular immune function was measured in-vitro by DNA synthesis, ornithine decarboxylase (ODC) activity and TNFalpha secretion. We found that both drugs have a comparable inhibitory effect on DNA synthesis, ODC activity and suppression of TNFalpha secretion. Exogenous addition of IL-2, did not restore the antiproliferative effect of both drugs. We conclude that budesonide has a comparative suppressive effect to methyl-prednisolone on the gut immune system which is not related to IL-2 secretion. The antiproliferative response may explain the therapeutic effect of budesonide on patients with inflammatory bowel disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect